Nicotine    (DrugBank: Nicotine)

2 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease9
84Sarcoidosis2

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03865121
(ClinicalTrials.gov)
March 4, 201926/2/2019Pilot Trial of Transnasal Nicotine in Parkinson DiseaseUncontrolled Pilot Trial of Transnasal Nicotine in Parkinson DiseaseParkinson DiseaseDrug: Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezHoward UniversityCompleted60 YearsN/AAll6Phase 2Mexico
2NCT02452125
(ClinicalTrials.gov)
May 201520/5/2015The Effects of Nicotine Chewing Gum in Parkinson's DiseaseThe Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's DiseaseLow Blood Pressure;Parkinsons DiseaseDietary Supplement: Nicotine gumNew York Institute of TechnologyNULLCompletedN/AN/AAll10N/AUnited States
3JPRN-UMIN000016664
2015/03/0101/03/2015Effect of nicotine patch in Cognitive function improvement in Parkinson's disease Parkinson's diseasenicotine patchDepartment of Clinical Pharmacology and Neurology Ehime University graduated School of MedicineNULLRecruitingNot applicableNot applicableMale and Female20Not selectedJapan
4NCT01560754
(ClinicalTrials.gov)
October 20129/3/2012Disease-modifying Potential of Transdermal NICotine in Early Parkinson's DiseaseA Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USAParkinson's DiseaseDrug: nicotine transdermal patchJames BOYD MDMichael J. Fox Foundation for Parkinson's Research;Parkinson Study Group (PSG);International Parkinson Fonds (IPF);German Parkinson Study Group (GPS);German Parkinson Society (DPG);Philipps-University Marburg, GermanyActive, not recruiting30 YearsN/ABoth160Phase 2United States;Germany
5EUCTR2010-020299-42-DE
(EUCTR)
30/08/201126/04/2011A study in U.S. and Germany to show if patients with an early stage of Parkinson's disease could be treated with a nicotine patch. In this study the nicotine patch is being compared to a placebo patch. The placebo patch is identical in appearance to the nicotine patch but does not contain any active ingredients.A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) - NIC-PD Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor therapy allowed
MedDRA version: 16.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Nicotinell 17,5 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE
Trade Name: Nicotinell 35 mg/24-Stunden-Pflaster
Product Name: Nicotinell
Other descriptive name: NICOTINE
Philipps-University MarburgNULLNot RecruitingFemale: yes
Male: yes
160Phase 2United States;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01216904
(ClinicalTrials.gov)
October 20106/10/2010Nicotine Treatment of Impulsivity in Parkinson's DiseaseNicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot StudyParkinson's DiseaseDrug: nicotine patch;Drug: placeboUniversity of VermontParkinson's Disease Foundation;The Parkinson Study GroupRecruiting18 YearsN/ABoth20Phase 4United States
7NCT00957918
(ClinicalTrials.gov)
October 200911/8/2009Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa TherapyRandomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa TherapyParkinson's DiseaseDrug: nicotine;Other: placebo comparatorNeuraltus Pharmaceuticals, Inc.NULLCompleted30 Years83 YearsBoth65Phase 1;Phase 2United States
8NCT00873392
(ClinicalTrials.gov)
February 200931/3/2009Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's DiseaseEfficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.Idiopathic Parkinson's DiseaseDrug: Transdermal nicotine;Other: Usual drug treatment of Parkinson's diseaseAssistance Publique - Hôpitaux de ParisNULLCompleted35 Years70 YearsBoth40Phase 2France
9EUCTR2008-001336-13-FR
(EUCTR)
16/07/200809/06/2008Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple insu sur 40 patients. - NICOPARK2 Maladie Parkinson
MedDRA version: 8.1;Level: PT;Classification code 10061536;Term: Parkinson's disease
Trade Name: Nicorette 5 mg/ 16 h
Product Name: Nicorette 5 mg/ 16 h
INN or Proposed INN: Nicotine
Product Name: Nicorette 10mg/ 16 h
INN or Proposed INN: Nicotine
Product Name: Nicorette 15 mg/ 16 h
INN or Proposed INN: Nicotine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France

84. Sarcoidosis    [ 143 clinical trials,   221 drugs,   (DrugBank: 79 drugs),   82 drug target genes,   165 drug target pathways]
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 143 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02265874
(ClinicalTrials.gov)
October 201410/10/2014Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudyNicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudySarcoidosisDrug: Habitrol;Drug: Placebo to HabitrolOhio State UniversityThe Cleveland ClinicRecruiting18 Years75 YearsAll60Phase 1;Phase 2United States
2NCT00701207
(ClinicalTrials.gov)
July 200817/6/2008Study of Nicotine Patches in Patients With SarcoidosisModulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine ReceptorsPulmonary SarcoidosisDrug: nicotine patchElliott Crouser MDAmerican Thoracic SocietySuspended18 YearsN/ABoth64Phase 4United States